Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
FiercePharma2h
Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
STOXX 600 inches lower at start of Christmas week; Novo Nordisk surges
Europe's STOXX 600 was slightly down at the start of a holiday-shortened week, after clocking its steepest weekly drop since ...
Xerox-Lexmark, Novo Nordisk, News Corp: 3 stories in focus
Brief's Brad Smith and Brian Sozzi examine the top stories on Wall Street, providing investors with a quick overview of what they need to know. Xerox (XRX) is set to acquire Lexmark in a $1.5 billion ...
Novo Nordisk shares rebound 8%: can European markets sustain the rally?
European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...
Bloomberg L.P.2d
Novo Nordisk cae tras revés en mercado de pérdida de peso
Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...